YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo
Phase 1/2Completed 0 watching 0 views this week⚡ Active
41
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Functional Constipation
Conditions
Functional Constipation
Trial Timeline
Aug 1, 2015 → Sep 1, 2016
NCT ID
NCT02538367About YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo
YH12852 IR 0.05mg + YH12852 IR 0.1mg + YH12852 IR 0.3mg + YH12852 IR 0.5mg + YH12852 IR 1mg + YH12852 IR 2mg + YH12852 IR 3mg + YH12852 DR1 0.5mg + YH12852 DR1 1mg + YH12852 DR1 2mg + YH12852 DR1 4mg + YH12852 DR2 8mg + Prucalopride 2mg + Placebo is a phase 1/2 stage product being developed by Yuhan for Functional Constipation. The current trial status is completed. This product is registered under clinical trial identifier NCT02538367. Target conditions include Functional Constipation.
Hype Score Breakdown
Clinical
13
Activity
8
Company
10
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02538367 | Phase 1/2 | Completed |
Competing Products
20 competing products in Functional Constipation
Other Products from Yuhan
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)Approved
85
Pregabalin 150mg + Alpha-lipoic acid 480mg + Pregabalin 150mg + Alpha-Lipoic Acid 480mgApproved
85
Anplag Tab. 100mg bid + Anplag Tab. 100mg tidApproved
85
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg + Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mgApproved
85
Atorvastatin 20mg loading + Atorvastatin 80mg loadingApproved
85